Document is current
Any future updates will be listed below
-
Authors
Harkos, Constantinos https://orcid.org/0000-0003-0261-1289
Hadjigeorgiou, Andreas G. https://orcid.org/0000-0003-2484-0074
Voutouri, Chrysovalantis https://orcid.org/0000-0003-3172-9489
Kumar, Ashwin S.
Stylianopoulos, Triantafyllos https://orcid.org/0000-0002-3093-1696
Jain, Rakesh K. https://orcid.org/0000-0001-7571-3548
- License Information
-
More Information
Article History
Accepted: 30 January 2025
First Online: 19 February 2025
Competing interests
: R.K.J. received consultant fees from DynamiCure, SPARC and SynDevRx; owns equity in Accurius, Enlight, SynDevRx; and served on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund; and received grants from Boehringer Ingelheim and Sanofi. Neither any reagent nor any funding from these organizations was used in this study. Other co-authors have no conflict of interests to declare.
